NasdaqGS:MGNX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States.


Snowflake Analysis

Excellent balance sheet with limited growth.

Share Price & News

How has MacroGenics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MGNX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

1.2%

MGNX

1.6%

US Biotechs

1.1%

US Market


1 Year Return

38.0%

MGNX

23.8%

US Biotechs

4.6%

US Market

Return vs Industry: MGNX exceeded the US Biotechs industry which returned 23.6% over the past year.

Return vs Market: MGNX exceeded the US Market which returned 4.1% over the past year.


Shareholder returns

MGNXIndustryMarket
7 Day1.2%1.6%1.1%
30 Day248.0%4.5%5.5%
90 Day111.2%11.0%-4.9%
1 Year38.0%38.0%25.0%23.8%7.0%4.6%
3 Year42.8%42.8%35.8%31.3%28.6%20.1%
5 Year-21.3%-21.3%-2.3%-8.2%52.5%35.3%

Price Volatility Vs. Market

How volatile is MacroGenics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is MacroGenics undervalued compared to its fair value and its price relative to the market?

6.54x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: MGNX ($25.37) is trading above our estimate of fair value ($5.07)

Significantly Below Fair Value: MGNX is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: MGNX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: MGNX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MGNX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MGNX is overvalued based on its PB Ratio (6.5x) compared to the US Biotechs industry average (3.8x).


Next Steps

Future Growth

How is MacroGenics forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

11.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MGNX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MGNX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MGNX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MGNX's revenue (22.2% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: MGNX's revenue (22.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MGNX is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has MacroGenics performed over the past 5 years?

-37.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MGNX is currently unprofitable.

Growing Profit Margin: MGNX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MGNX is unprofitable, and losses have increased over the past 5 years at a rate of -37.3% per year.

Accelerating Growth: Unable to compare MGNX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MGNX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: MGNX has a negative Return on Equity (-79.51%), as it is currently unprofitable.


Next Steps

Financial Health

How is MacroGenics's financial position?


Financial Position Analysis

Short Term Liabilities: MGNX's short term assets ($195.3M) exceed its short term liabilities ($39.6M).

Long Term Liabilities: MGNX's short term assets ($195.3M) exceed its long term liabilities ($35.2M).


Debt to Equity History and Analysis

Debt Level: MGNX is debt free.

Reducing Debt: MGNX has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MGNX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: MGNX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 33.8% each year


Next Steps

Dividend

What is MacroGenics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MGNX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MGNX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MGNX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MGNX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MGNX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

7.8yrs

Average management tenure


CEO

Scott Koenig (67yo)

18.67yrs

Tenure

US$4,723,588

Compensation

Dr. Scott Koenig, M.D., Ph.D., has been the President and Chief Executive Officer of Macrogenics, Inc. since September 2001. Dr. Koenig served as Senior Vice President of Research at MedImmune Inc., where  ...


CEO Compensation Analysis

Compensation vs Market: Scott's total compensation ($USD4.72M) is about average for companies of similar size in the US market ($USD4.91M).

Compensation vs Earnings: Scott's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Scott Koenig
CEO, President & Director18.67yrsUS$4.72m2.37% $29.5m
James Karrels
Senior VP12yrsUS$1.78m0.31% $3.9m
Ezio Bonvini
Senior VP of Research3.67yrsUS$1.90m0.31% $3.9m
Eric Risser
Senior VP of Business Development & Portfolio Management and Chief Business Officer3.67yrsUS$1.78m0.090% $1.1m
Anna Krassowska
Vice President of Investor Relations & Corporate Communicationsno datano datano data
Jeffrey Peters
VP & General Counsel2.92yrsno data0.00041% $5.1k
Thomas Spitznagel
Senior Vice President of BioPharmaceutical Development & Manufacturingno datano datano data
Lynn Cilinski
VP, Controller & Treasurer16.58yrsno datano data

7.8yrs

Average Tenure

52yo

Average Age

Experienced Management: MGNX's management team is seasoned and experienced (7.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Scott Koenig
CEO, President & Director18.67yrsUS$4.72m2.37% $29.5m
David Stump
Independent Director6.67yrsUS$176.53kno data
Edward Hurwitz
Independent Director15.58yrsUS$171.50k0.037% $458.5k
Kenneth Galbraith
Independent Director11.83yrsUS$187.47k0.095% $1.2m
Paulo Costa
Independent Chairman of the Board6.67yrsUS$210.46k0.12% $1.5m
Scott Jackson
Independent Director3.33yrsUS$175.47kno data
Jay Siegel
Independent Director2.5yrsUS$180.12kno data
Karen Jean Ferrante
Independent Director3.33yrsUS$176.53kno data

6.7yrs

Average Tenure

63.5yo

Average Age

Experienced Board: MGNX's board of directors are considered experienced (6.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

MacroGenics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: MacroGenics, Inc.
  • Ticker: MGNX
  • Exchange: NasdaqGS
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.247b
  • Shares outstanding: 49.14m
  • Website: https://www.macrogenics.com

Number of Employees


Location

  • MacroGenics, Inc.
  • 9704 Medical Center Drive
  • Rockville
  • Maryland
  • 20850
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MGNXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDOct 2013
M55DB (Deutsche Boerse AG)YesCommon StockDEEUROct 2013

Biography

MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3 for treating acute myeloid leukemia; MGA012, an investigational monoclonal antibody targeting PD-1; MGD013, a monoclonal antibody that targets the PD-1 and lymphocyte-activation gene 3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and Enoblituzumab, a monoclonal antibody that targets B7-H3. In addition, the company is developing combination of MGD009 and MGA012; MGC018, an antibody drug conjugate, which targets solid tumors expressing B7-H3; and MGD014, a DART molecule that targets envelope protein of human immunodeficiency virus infected cells and T cells. It has strategic collaborations with Incyte Corporation; Zai Lab Limited; and I-Mab Biopharma. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/26 05:38
End of Day Share Price2020/05/22 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.